Table 2. Selection of predictors for multivariable modelling.
| Selected predictors | Preterm Preeclampsia; FDR: 59% | Term Preeclampsia; FDR: 7.4% | Preeclampsia; FDR: 2.8% | |||
|---|---|---|---|---|---|---|
| AUROC (95%CI) | Effect size (95%CI) | AUROC (95%CI) | Effect size (95%CI) | AUROC (95%CI) | Effect size (95%CI) | |
| MAP | N/P | N/A | 0.69 (0.63–0.76) | ↑ 5.3 mmHg (3.3–7.7) | 0.67 (0.61–0.73) | ↑ 4.7 mmHg (2.7–6.7) |
| BMI | 0.65 (0.54–0.75) | ↑ 1.9 kg/m2 (0.4–3.5) | 0.63 (0.56–0.70) | ↑ 2.0 kg/m2 (0.9–3.1) | 0.64 (0.57–0.70) | ↑ 2.0 kg/m2 (1.0–2.9) |
| DLG | 0.70 (0.59–0.82) | ↑ 1.45 (1.18–1.78) | N/P | N/A | 0.61 (0.55–0.67) | ↑ 1.23 (1.09–1.37) |
| Choline | 0.61 (0.50–0.72) | ↑ 1.09 (0.99–1.20) | N/P | N/A | N/P | N/A |
| Isoleucine | N/P | N/A | 0.61 (0.54–0.68) | ↑ 1.12 (1.04–1.20) | N/P | N/A |
| 1-HGP | N/P | N/A | 0.61 (0.53–0.68) | ↓ 0.89 (0.82–0.96) | 0.61 (0.54–0.67) | ↓ 0.89 (0.83–0.95) |
| 2-Hydroxybutanoic acid | 0.62 (0.50–0.73) | ↑ 1.16 (0.99–1.37) | N/P | N/A | N/P | N/A |
| NG-monomethyl-L-arginine | 0.61 (0.50–0.72) | ↑ 1.08 (0.99–1.18) | N/P | N/A | N/P | N/A |
| Decanoylcarnitine | N/P | N/A | 0.60 (0.53–0.67) | ↑ 1.32 (1.08–1.63) | N/P | N/A |
| PlGF | 0.73 (061–0.85) | ↓ 0.43 (0.29–0.89) | N/P | N/A | 0.60 (0.53–0.67) | ↓ 0.71 (0.57–0.89) |
Predictor selection based on predictive performance as a single marker (AUROC >0.60, LCI ≥0.50) and median effect size* compared to controls.
*Effect size: median difference for BMI and MAP and median fold change for analyte concentration (95% confidence interval); AUROC = area under the receiver operating curve (95% confidence interval); LCI = lower confident interval; CI = confident interval; N/P = No predictive performance; N/A = Not applicable; MAP = Mean Arterial Pressure; BMI = Body mass index; DLG = Dilinoleoyl-glycerol; 1-HGP = 1-Heptadecanoyl-2-hydroxy-sn-glycero-3 phosphocholine
↑ = up-regulated compared to controls
↓ = down-regulated compared to controls; FDR = false discovery rate.